Get vendors


Ligand source activities (1 row/activity)

Ligand Receptor Assay information Chemical information
Sel. page Common
name
GPCRdb ID #Vendors UniProt IUPHAR Species p-value
(-log)
Activity
Type
Activity
Relation
Activity
Value
Assay Type Assay Description Source Mol
weight
Rot
Bonds
H don H acc LogP Smiles DOI
8497 2573 45 CXCR2 CXCR2 Human 10.3 pIC50 = 10.3 Binding
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/jm300682j
9865554 2573 45 CXCR2 CXCR2 Human 10.3 pIC50 = 10.3 Binding
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/jm300682j
CHEMBL216981 2573 45 CXCR2 CXCR2 Human 10.3 pIC50 = 10.3 Binding
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/jm300682j
11372270 66935 13 CXCR2 CXCR2 Human 10.0 pIC50 = 10 Binding
Inhibition of CXCR2 (unknown origin)Inhibition of CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1021/acs.jmedchem.8b00875
CHEMBL189475 66935 13 CXCR2 CXCR2 Human 10.0 pIC50 = 10 Binding
Inhibition of CXCR2 (unknown origin)Inhibition of CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1021/acs.jmedchem.8b00875
CHEMBL4442431 66935 13 CXCR2 CXCR2 Human 10.0 pIC50 = 10 Binding
Inhibition of CXCR2 (unknown origin)Inhibition of CXCR2 (unknown origin)
ChEMBL 375 5 1 6 1.1 C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1 10.1021/acs.jmedchem.8b00875
88545431 170554 0 CXCR2 CXCR2 Mouse 10.0 pIC50 = 10 Binding
Inhibition of CXCR2-mediated chemotaxis in mouse BAF3 cellsInhibition of CXCR2-mediated chemotaxis in mouse BAF3 cells
ChEMBL 478 7 3 8 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN4CCC[C@H]4C3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.ejmech.2019.111853
CHEMBL4462143 170554 0 CXCR2 CXCR2 Mouse 10.0 pIC50 = 10 Binding
Inhibition of CXCR2-mediated chemotaxis in mouse BAF3 cellsInhibition of CXCR2-mediated chemotaxis in mouse BAF3 cells
ChEMBL 478 7 3 8 3.1 CC[C@@H](Nc1c(Nc2cccc(C(=O)N3CCN4CCC[C@H]4C3)c2O)c(=O)c1=O)c1ccc(C)o1 10.1016/j.ejmech.2019.111853
44626319 192011 0 CXCR2 CXCR2 Human 9.9 pIC50 = 9.9 Binding
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.ejmech.2019.111853
CHEMBL577075 192011 0 CXCR2 CXCR2 Human 9.9 pIC50 = 9.9 Binding
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 346 7 3 7 1.1 CCN(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.ejmech.2019.111853
137633598 155620 0 CXCR2 CXCR2 Human 9.8 pIC50 = 9.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 445 5 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)CC(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4066904 155620 0 CXCR2 CXCR2 Human 9.8 pIC50 = 9.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 445 5 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)CC(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
118540892 156910 0 CXCR2 CXCR2 Human 9.7 pIC50 = 9.7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 377 3 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4082136 156910 0 CXCR2 CXCR2 Human 9.7 pIC50 = 9.7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 377 3 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
118554832 158408 0 CXCR2 CXCR2 Human 9.7 pIC50 = 9.7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 432 4 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4098864 158408 0 CXCR2 CXCR2 Human 9.7 pIC50 = 9.7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 432 4 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4128926 160742 0 CXCR2 CXCR2 Human 9.6 pIC50 = 9.6 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor after 60 mins by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor after 60 mins by scintillation counting analysis
ChEMBL 583 8 3 6 5.8 CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12 10.1016/j.bmcl.2018.03.093
129316069 155045 0 CXCR2 CXCR2 Human 9.6 pIC50 = 9.6 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 436 6 4 5 3.4 CC(C)(CCO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4060139 155045 0 CXCR2 CXCR2 Human 9.6 pIC50 = 9.6 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 436 6 4 5 3.4 CC(C)(CCO)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
118554743 155225 0 CXCR2 CXCR2 Human 9.6 pIC50 = 9.6 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 5 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2COC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4062361 155225 0 CXCR2 CXCR2 Human 9.6 pIC50 = 9.6 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 5 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2COC2)c1O 10.1021/acs.jmedchem.7b01854
118540867 156095 0 CXCR2 CXCR2 Human 9.6 pIC50 = 9.6 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 4 5 3.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CC[C@@H](O)C2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4072270 156095 0 CXCR2 CXCR2 Human 9.6 pIC50 = 9.6 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 4 5 3.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@H]2CC[C@@H](O)C2)c1O 10.1021/acs.jmedchem.7b01854
129316028 156498 0 CXCR2 CXCR2 Human 9.5 pIC50 = 9.5 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 4.0 CCC1(S(=O)(=O)c2c(Cl)ccc(NC(=O)N[C@@H]3CCC=C3C)c2O)CCOCC1 10.1021/acs.jmedchem.7b01854
CHEMBL4077201 156498 0 CXCR2 CXCR2 Human 9.5 pIC50 = 9.5 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 4.0 CCC1(S(=O)(=O)c2c(Cl)ccc(NC(=O)N[C@@H]3CCC=C3C)c2O)CCOCC1 10.1021/acs.jmedchem.7b01854
58180205 140005 0 CXCR2 CXCR2 Human 9.5 pIC50 = 9.5 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 446 4 3 4 5.2 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818853 140005 0 CXCR2 CXCR2 Human 9.5 pIC50 = 9.5 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 446 4 3 4 5.2 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
58180198 140017 0 CXCR2 CXCR2 Human 9.5 pIC50 = 9.5 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 432 4 3 4 4.8 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818984 140017 0 CXCR2 CXCR2 Human 9.5 pIC50 = 9.5 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 432 4 3 4 4.8 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
58180199 140051 0 CXCR2 CXCR2 Human 9.5 pIC50 = 9.5 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 460 4 3 4 5.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3819480 140051 0 CXCR2 CXCR2 Human 9.5 pIC50 = 9.5 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 460 4 3 4 5.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
127049431 139931 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL3817901 139931 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acs.jmedchem.7b01854
123190913 155614 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.5 CC1=CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4066818 155614 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.5 CC1=CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
129316018 155927 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 467 5 3 5 4.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(C3CCC3)CC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4070506 155927 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 467 5 3 5 4.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(C3CCC3)CC2)c1O 10.1021/acs.jmedchem.7b01854
118540730 157301 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 394 4 3 4 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4086957 157301 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 394 4 3 4 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(F)F)c1O 10.1021/acs.jmedchem.7b01854
127052173 139984 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 543 4 3 5 5.9 CN1CCC2(CCC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)CC2)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818581 139984 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 543 4 3 5 5.9 CN1CCC2(CCC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)CC2)CC1 10.1021/acsmedchemlett.5b00489
127051854 140025 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 487 4 3 5 4.4 CN1CC2(CC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)C2)C1 10.1021/acsmedchemlett.5b00489
CHEMBL3819163 140025 0 CXCR2 CXCR2 Human 9.4 pIC50 = 9.4 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 487 4 3 5 4.4 CN1CC2(CC(S(=O)(=O)c3c(Cl)ccc(NC(=O)Nc4cccc(F)c4Cl)c3O)C2)C1 10.1021/acsmedchemlett.5b00489
118554794 155592 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4066510 155592 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
118554809 156898 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 452 4 3 5 3.7 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O)N[C@@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
CHEMBL4082031 156898 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 452 4 3 5 3.7 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O)N[C@@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
118554742 157429 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 456 5 3 5 4.3 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4088551 157429 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 456 5 3 5 4.3 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
118554882 158792 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 440 4 3 4 4.4 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4103349 158792 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 440 4 3 4 4.4 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
127049431 139931 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3817901 139931 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
127049370 139959 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 461 4 3 5 4.0 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
CHEMBL3818277 139959 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 461 4 3 5 4.0 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
127048710 139999 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 464 4 3 5 4.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818793 139999 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 464 4 3 5 4.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
127049371 140004 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 489 4 3 5 4.7 CN1CCC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818827 140004 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 489 4 3 5 4.7 CN1CCC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127050964 140032 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 425 3 3 3 5.1 O=C(Nc1ccc(Cl)c(C(=O)N2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3819221 140032 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 425 3 3 3 5.1 O=C(Nc1ccc(Cl)c(C(=O)N2CCCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
127049430 140039 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 422 4 3 4 4.8 CCS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3819295 140039 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 422 4 3 4 4.8 CCS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
127020968 140053 17 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 475 4 3 5 4.4 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819512 140053 17 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 475 4 3 5 4.4 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127051212 140059 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 434 3 3 4 5.1 CC(C)(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3819569 140059 0 CXCR2 CXCR2 Human 9.3 pIC50 = 9.3 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 434 3 3 4 5.1 CC(C)(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
129315964 156635 0 CXCR2 CXCR2 Human 9.2 pIC50 = 9.2 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 404 5 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CF)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4079102 156635 0 CXCR2 CXCR2 Human 9.2 pIC50 = 9.2 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 404 5 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CF)c1O 10.1021/acs.jmedchem.7b01854
118554787 158416 0 CXCR2 CXCR2 Human 9.2 pIC50 = 9.2 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 459 6 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CCF)CC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4098979 158416 0 CXCR2 CXCR2 Human 9.2 pIC50 = 9.2 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 459 6 3 5 3.5 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCN(CCF)CC2)c1O 10.1021/acs.jmedchem.7b01854
127049432 139954 0 CXCR2 CXCR2 Human 9.2 pIC50 = 9.2 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 436 4 3 4 5.2 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3818216 139954 0 CXCR2 CXCR2 Human 9.2 pIC50 = 9.2 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 436 4 3 4 5.2 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
11599650 139975 0 CXCR2 CXCR2 Human 9.2 pIC50 = 9.2 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 478 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818458 139975 0 CXCR2 CXCR2 Human 9.2 pIC50 = 9.2 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 478 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
118554754 157518 0 CXCR2 CXCR2 Human 9.1 pIC50 = 9.1 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 418 4 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4089421 157518 0 CXCR2 CXCR2 Human 9.1 pIC50 = 9.1 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 418 4 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
127050016 140002 0 CXCR2 CXCR2 Human 9.1 pIC50 = 9.1 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 478 4 3 5 4.9 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818820 140002 0 CXCR2 CXCR2 Human 9.1 pIC50 = 9.1 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 478 4 3 5 4.9 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCOCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
9956678 140010 0 CXCR2 CXCR2 Human 9.1 pIC50 = 9.1 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 476 4 3 5 3.4 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818917 140010 0 CXCR2 CXCR2 Human 9.1 pIC50 = 9.1 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 476 4 3 5 3.4 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127049422 140056 0 CXCR2 CXCR2 Human 9.1 pIC50 = 9.1 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 492 4 3 5 3.9 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819542 140056 0 CXCR2 CXCR2 Human 9.1 pIC50 = 9.1 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 492 4 3 5 3.9 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
8498 3114 38 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Functional
Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxisAntagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
9838712 3114 38 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Functional
Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxisAntagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
CHEMBL191413 3114 38 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Functional
Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxisAntagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
DB12614 3114 38 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Functional
Antagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxisAntagonist activity at CXCR2 assessed as inhibition of CXCL8-induced neutrophil chemotaxis
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
100951623 155662 4 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4067429 155662 4 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
118554834 156396 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 426 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CC3(COC3)C2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4076053 156396 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 426 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CC3(COC3)C2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4076428 156422 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 453 5 3 5 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N3CCCC3)C2)c1O 10.1021/acs.jmedchem.7b01854
118554836 157973 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 392 4 3 4 3.6 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4094324 157973 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 392 4 3 4 3.6 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
130191301 158099 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 3 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4095602 158099 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 3 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4097602 158286 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 427 5 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N(C)C)C2)c1O 10.1021/acs.jmedchem.7b01854
118540525 158565 2 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4100674 158565 2 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
127052174 139964 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 411 3 3 3 4.7 O=C(Nc1ccc(Cl)c(C(=O)N2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818323 139964 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 411 3 3 3 4.7 O=C(Nc1ccc(Cl)c(C(=O)N2CCCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
127049108 140045 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 490 5 3 5 3.8 CCN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819382 140045 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 490 5 3 5 3.8 CCN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
12073810 170713 3 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2015.01.067
CHEMBL446458 170713 3 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2015.01.067
44455014 94666 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 379 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)cnc12 10.1016/j.bmcl.2007.11.039
CHEMBL256668 94666 0 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 379 6 3 7 2.1 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)cnc12 10.1016/j.bmcl.2007.11.039
11858154 154533 10 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 400 6 3 7 3.3 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL403225 154533 10 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 400 6 3 7 3.3 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
12073810 170713 3 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL446458 170713 3 CXCR2 CXCR2 Human 9.0 pIC50 = 9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 384 6 3 7 2.7 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)sc12 10.1016/j.bmcl.2007.11.039
118540528 155242 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4062546 155242 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
129316053 156427 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4076478 156427 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
118554755 156690 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 446 5 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(CF)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4079718 156690 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 446 5 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(CF)CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
129315983 157071 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 402 6 3 5 3.1 COCC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4084077 157071 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 402 6 3 5 3.1 COCC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)N[C@@H]2CCC=C2C)c1O 10.1021/acs.jmedchem.7b01854
127049049 139949 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 477 4 3 5 4.5 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
CHEMBL3818179 139949 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 477 4 3 5 4.5 CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C1 10.1021/acsmedchemlett.5b00489
127049048 139965 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 489 5 3 5 4.7 CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818331 139965 0 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 489 5 3 5 4.7 CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
10310100 92804 31 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 425 8 3 7 3.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C(C)C)co1 10.1016/j.bmcl.2007.04.016
CHEMBL246108 92804 31 CXCR2 CXCR2 Human 8.9 pIC50 = 8.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPADisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells by SPA
ChEMBL 425 8 3 7 3.7 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C(C)C)co1 10.1016/j.bmcl.2007.04.016
129316073 156894 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4081963 156894 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
129315999 157075 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4084135 157075 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 442 5 3 5 3.9 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)[C@H]2CCOC2)c1O 10.1021/acs.jmedchem.7b01854
118540796 158369 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 390 4 3 4 3.8 CC1=C(F)CCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4098536 158369 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 390 4 3 4 3.8 CC1=C(F)CCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
127049047 140055 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 491 4 3 5 4.9 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819521 140055 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 491 4 3 5 4.9 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127049427 140062 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 504 5 3 5 4.2 CC(C)N1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819603 140062 0 CXCR2 CXCR2 Human 8.8 pIC50 = 8.8 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 504 5 3 5 4.2 CC(C)N1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
129316076 155033 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4060060 155033 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 428 4 3 5 3.6 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCCOC2)c1O 10.1021/acs.jmedchem.7b01854
129316027 156071 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 437 6 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(F)(F)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4072010 156071 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 437 6 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(F)(F)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
127052172 140023 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 515 4 3 5 5.1 CN1CCC2(CC1)CC(S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c1O)C2 10.1021/acsmedchemlett.5b00489
CHEMBL3819070 140023 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 515 4 3 5 5.1 CN1CCC2(CC1)CC(S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c1O)C2 10.1021/acsmedchemlett.5b00489
127050017 139958 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 477 4 4 5 4.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818269 139958 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 477 4 4 5 4.5 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
127052172 140023 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 515 4 3 5 5.1 CN1CCC2(CC1)CC(S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c1O)C2 10.1021/acsmedchemlett.5b00489
CHEMBL3819070 140023 0 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 515 4 3 5 5.1 CN1CCC2(CC1)CC(S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c1O)C2 10.1021/acsmedchemlett.5b00489
9887803 140038 19 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 409 3 4 4 3.6 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3819292 140038 19 CXCR2 CXCR2 Human 8.7 pIC50 = 8.7 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 409 3 4 4 3.6 NS(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
135907804 112221 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 363 5 2 6 2.8 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1[C@H]1C[C@@H]1C(=O)O 10.1016/j.bmcl.2014.06.011
CHEMBL3310786 112221 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 363 5 2 6 2.8 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1[C@H]1C[C@@H]1C(=O)O 10.1016/j.bmcl.2014.06.011
123227682 155399 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 4 3.4 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4064349 155399 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 4 3.4 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCC=C2F)c1O 10.1021/acs.jmedchem.7b01854
137633482 155788 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 4 4.0 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4068799 155788 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 406 4 3 4 4.0 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC=C2Cl)c1O 10.1021/acs.jmedchem.7b01854
137638965 156052 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 374 4 3 4 3.5 CC1CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4071768 156052 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 374 4 3 4 3.5 CC1CCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
137644508 157651 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2C=CCCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4090813 157651 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 372 4 3 4 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2C=CCCC2)c1O 10.1021/acs.jmedchem.7b01854
137654230 157886 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 360 4 3 4 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4093313 157886 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 360 4 3 4 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC2)c1O 10.1021/acs.jmedchem.7b01854
127049431 139931 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3817901 139931 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 420 4 3 4 4.7 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(F)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
127049429 139927 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 507 4 3 5 4.8 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
CHEMBL3817880 139927 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Antagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubationAntagonist activity at human recombinant Gal4-VP16 fused-CXCR2 assessed as inhibition of CXCL1-mediated lactamase reporter gene expression after overnight incubation
ChEMBL 507 4 3 5 4.8 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
8497 2573 45 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Functional
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acsmedchemlett.1c00113
9865554 2573 45 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Functional
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acsmedchemlett.1c00113
CHEMBL216981 2573 45 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Functional
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 397 7 3 7 2.9 CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C 10.1021/acsmedchemlett.1c00113
CHEMBL4742368 178744 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Functional
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 413 4 3 6 3.1 CC(C)S(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)[C@@H](C3CCCCC3)N2)c1O 10.1021/acsmedchemlett.1c00113
44393541 65591 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 383 3 4 3 3.6 NC(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL184185 65591 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 383 3 4 3 3.6 NC(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
9841667 139950 39 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/s0960-894x(02)00188-9
CHEMBL38182 139950 39 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/s0960-894x(02)00188-9
57833135 117282 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 422 8 3 7 2.8 C[C@H](CO)Nc1cc(NS(=O)(=O)C(F)(F)F)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403840 117282 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 422 8 3 7 2.8 C[C@H](CO)Nc1cc(NS(=O)(=O)C(F)(F)F)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL213130 79445 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 357 3 3 6 1.8 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCCCC2)c1O 10.1016/j.bmcl.2006.04.082
CHEMBL375175 136453 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 317 3 3 6 0.9 CC(C)/N=c1\c(O)c(O)\c1=N/c1cccc(C(=O)N(C)C)c1O 10.1016/j.bmcl.2006.04.082
44439708 13608 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 568 6 3 8 3.2 CN1CCCN(S(=O)(=O)c2c(Cl)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL1196279 13608 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 568 6 3 8 3.2 CN1CCCN(S(=O)(=O)c2c(Cl)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL556367 13608 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 568 6 3 8 3.2 CN1CCCN(S(=O)(=O)c2c(Cl)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
44446608 94002 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8.0 Binding
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 384 7 3 8 2.0 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cocn1 10.1016/j.bmcl.2008.01.024
CHEMBL252697 94002 0 CXCR2 CXCR2 Human 8.0 pIC50 = 8.0 Binding
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 384 7 3 8 2.0 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cocn1 10.1016/j.bmcl.2008.01.024
136087088 115245 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 453 5 3 6 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)C(F)(F)F)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355242 115245 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 453 5 3 6 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)C(F)(F)F)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
45485775 191275 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Functional
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 424 8 3 8 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(OC)cc1 10.1016/j.bmcl.2009.08.014
CHEMBL571141 191275 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Functional
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 424 8 3 8 2.3 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(OC)cc1 10.1016/j.bmcl.2009.08.014
CHEMBL4076428 156422 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 453 5 3 5 3.7 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N3CCCC3)C2)c1O 10.1021/acs.jmedchem.7b01854
129315964 156635 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 404 5 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CF)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4079102 156635 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 404 5 3 4 3.8 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CF)c1O 10.1021/acs.jmedchem.7b01854
129316030 157378 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 452 4 3 5 3.7 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O)N[C@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
CHEMBL4087900 157378 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 452 4 3 5 3.7 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2(F)CCOCC2)c1O)N[C@H]1CCC=C1Cl 10.1021/acs.jmedchem.7b01854
127049371 140004 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 489 4 3 5 4.7 CN1CCC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818827 140004 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 489 4 3 5 4.7 CN1CCC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
8498 3114 38 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
9838712 3114 38 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
CHEMBL191413 3114 38 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
DB12614 3114 38 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Binding affinity to CXCR2Binding affinity to CXCR2
ChEMBL 283 5 1 3 2.1 CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C 10.1021/jm300682j
9946476 86675 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 351 6 3 9 2.7 CC(C)(CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL233262 86675 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 351 6 3 9 2.7 CC(C)(CO)Nc1nc(SCc2ccco2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44431193 149581 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 3 8 4.7 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC(C)C)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL395340 149581 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 3 8 4.7 CC[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC(C)C)sc12 10.1016/j.bmcl.2007.02.080
44431186 166933 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 4 9 3.0 OCC(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC3CC3)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL430381 166933 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 439 9 4 9 3.0 OCC(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(NC3CC3)sc12 10.1016/j.bmcl.2007.02.080
71555295 132019 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 565 8 3 10 3.8 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC[C@@H]4C(=O)OC(C)(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701187 132019 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 565 8 3 10 3.8 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC[C@@H]4C(=O)OC(C)(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
71555297 132022 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 438 8 3 8 3.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)C(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701190 132022 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 438 8 3 8 3.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)C(C)C)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
137633598 155620 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 445 5 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)CC(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4066904 155620 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 445 5 3 5 4.0 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)CC(F)(F)F)c1O 10.1021/acs.jmedchem.7b01854
127049422 140056 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 492 4 3 5 3.9 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819542 140056 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 492 4 3 5 3.9 CN1CCN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
24970094 126028 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Functional
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 397 8 2 4 3.6 CC(C)(NC(=O)c1ccc2c(c1OCCOc1ccccc1)CCCC2)C(=O)O nan
CHEMBL3654434 126028 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Functional
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 397 8 2 4 3.6 CC(C)(NC(=O)c1ccc2c(c1OCCOc1ccccc1)CCCC2)C(=O)O nan
CHEMBL210448 77572 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 324 3 4 6 1.8 O=C(O)c1cccc(/N=c2\c(O)c(O)\c2=N/c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
22288470 86677 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 382 6 3 10 2.9 Cc1nc(CSc2nc(NC(C)(C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.02.080
CHEMBL233264 86677 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 382 6 3 10 2.9 Cc1nc(CSc2nc(NC(C)(C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.02.080
9795327 194382 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 266 2 1 2 2.4 O=C(Nc1ccc(F)cc1)c1ccc(Cl)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
CHEMBL60066 194382 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 266 2 1 2 2.4 O=C(Nc1ccc(F)cc1)c1ccc(Cl)[n+]([O-])c1 10.1016/s0960-894x(01)00326-2
9817855 199541 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 301 3 1 4 3.9 Sc1nc(-c2cccc(Cl)c2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
CHEMBL84755 199541 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 301 3 1 4 3.9 Sc1nc(-c2cccc(Cl)c2)nn1Cc1ccccc1 10.1016/s0960-894x(03)00561-4
136074345 112227 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(CSc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
CHEMBL3310793 112227 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(CSc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
11599650 139975 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 478 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818458 139975 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 478 4 4 5 3.6 O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(Cl)c1Cl 10.1021/acsmedchemlett.5b00489
135546485 72890 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 255 5 1 6 3.1 CCCCCSc1nc(O)c2scnc2n1 10.1016/j.bmcl.2005.10.091
CHEMBL201672 72890 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 255 5 1 6 3.1 CCCCCSc1nc(O)c2scnc2n1 10.1016/j.bmcl.2005.10.091
135673987 73078 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 270 5 2 7 2.7 CCCCCSc1nc(O)c2sc(N)nc2n1 10.1016/j.bmcl.2005.10.091
CHEMBL201799 73078 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 270 5 2 7 2.7 CCCCCSc1nc(O)c2sc(N)nc2n1 10.1016/j.bmcl.2005.10.091
44407558 73079 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 289 3 2 7 2.5 Nc1nc2nc(SCc3ccccc3)nc(N)c2s1 10.1016/j.bmcl.2005.10.091
CHEMBL201800 73079 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 289 3 2 7 2.5 Nc1nc2nc(SCc3ccccc3)nc(N)c2s1 10.1016/j.bmcl.2005.10.091
11329244 70540 7 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Inhibition of C-X-C chemokine receptor type 2Inhibition of C-X-C chemokine receptor type 2
ChEMBL 486 7 2 5 5.4 CC(=O)c1sc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C 10.1021/jm049530m
CHEMBL195433 70540 7 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Inhibition of C-X-C chemokine receptor type 2Inhibition of C-X-C chemokine receptor type 2
ChEMBL 486 7 2 5 5.4 CC(=O)c1sc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C 10.1021/jm049530m
11272103 123594 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Inhibition of C-X-C chemokine receptor type 2Inhibition of C-X-C chemokine receptor type 2
ChEMBL 505 7 2 6 4.7 Cn1nnnc1-c1cccc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)c1 10.1021/jm049530m
CHEMBL363840 123594 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Inhibition of C-X-C chemokine receptor type 2Inhibition of C-X-C chemokine receptor type 2
ChEMBL 505 7 2 6 4.7 Cn1nnnc1-c1cccc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)c1 10.1021/jm049530m
44318749 199539 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 365 4 1 5 4.6 COc1ccc(Cn2nc(-c3ccc(Cl)cc3Cl)nc2S)cc1 10.1016/s0960-894x(03)00561-4
CHEMBL84752 199539 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 365 4 1 5 4.6 COc1ccc(Cn2nc(-c3ccc(Cl)cc3Cl)nc2S)cc1 10.1016/s0960-894x(03)00561-4
91937340 126483 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 387 5 2 6 2.5 O=C(Nc1ccc(F)cn1)c1ccc(S(=O)(=O)Cc2ccccc2O)nc1 nan
CHEMBL3658347 126483 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 387 5 2 6 2.5 O=C(Nc1ccc(F)cn1)c1ccc(S(=O)(=O)Cc2ccccc2O)nc1 nan
CHEMBL1437942 34999 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 271 3 1 5 3.0 Cc1cc2nc(CSc3ccccc3)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
71525700 132532 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 399 7 3 9 2.2 COc1ccc(Nc2c(NC(c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c(O)n1 nan
CHEMBL3704566 132532 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 399 7 3 9 2.2 COc1ccc(Nc2c(NC(c3ccc(C)o3)C3(C)COC3)c(=O)c2=O)c(O)n1 nan
91937331 114189 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 380 6 4 6 2.0 O=C(Nc1ccc(O)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
CHEMBL3342318 114189 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Functional
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 380 6 4 6 2.0 O=C(Nc1ccc(O)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 10.1021/jm500827t
91937331 114189 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 380 6 4 6 2.0 O=C(Nc1ccc(O)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
CHEMBL3342318 114189 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 380 6 4 6 2.0 O=C(Nc1ccc(O)cc1)c1ccc(SCc2ccccc2B(O)O)nc1 nan
72948072 103915 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 319 5 1 5 2.3 COc1cc(CCc2cccc(F)c2F)nc2cc(CO)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104898 103915 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 319 5 1 5 2.3 COc1cc(CCc2cccc(F)c2F)nc2cc(CO)nn12 10.1016/j.bmcl.2013.11.074
71526066 143611 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 555 9 2 9 4.3 CCOC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1F nan
CHEMBL3906175 143611 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 555 9 2 9 4.3 CCOC(=O)[C@@H]1CCCN1C(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1F nan
71526603 132016 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 8 3 8 2.9 CCC1(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c2ccc(C)o2)COC1 nan
CHEMBL3701184 132016 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 453 8 3 8 2.9 CCC1(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)c2ccc(C)o2)COC1 nan
71525793 132527 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 441 7 3 8 2.7 CN(C)C(=O)c1cccc(Nc2c(NC(c3cccs3)C3(C)COC3)c(=O)c2=O)c1O nan
CHEMBL3704561 132527 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 441 7 3 8 2.7 CN(C)C(=O)c1cccc(Nc2c(NC(c3cccs3)C3(C)COC3)c(=O)c2=O)c1O nan
46897259 126035 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 480 7 1 6 5.6 CC(=O)Oc1ccc(OC(F)(F)F)cc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
CHEMBL3654442 126035 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 480 7 1 6 5.6 CC(=O)Oc1ccc(OC(F)(F)F)cc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
CHEMBL4800160 182672 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Binding
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 486 4 2 5 6.9 CC1CCCc2sc(NC(=S)Nc3ccc(OC(F)(F)F)cc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
71526607 132018 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 481 7 4 9 2.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CC[C@H](O)C4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
CHEMBL3701186 132018 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 481 7 4 9 2.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CC[C@H](O)C4)c3O)c(=O)c2=O)C2(C)COC2)o1 nan
71526065 152367 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 569 9 2 9 4.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC[C@H]4C(=O)OC(C)C)c3F)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3976863 152367 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 569 9 2 9 4.7 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N4CCC[C@H]4C(=O)OC(C)C)c3F)c(=O)c2=O)C2CCCS2)o1 nan
11818139 93422 2 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Binding
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccccc1)Nc1cc([N+](=O)[O-])ccc1O 10.1021/jm034248l
CHEMBL24912 93422 2 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Binding
Inhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligandInhibition of binding of IL-8 to membranes of cloned CXC chemokine receptor 2 expressed in CHO Cells using [125I]IL-8 radioligand
ChEMBL 273 3 3 4 2.9 O=C(Nc1ccccc1)Nc1cc([N+](=O)[O-])ccc1O 10.1021/jm034248l
9849040 152031 2 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
Compound binding was evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human C-X-C chemokine receptor type 2Compound binding was evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human C-X-C chemokine receptor type 2
ChEMBL 504 10 1 6 7.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1ccc(-c2cccs2)s1 10.1016/s0960-894x(01)00326-2
CHEMBL39740 152031 2 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
Compound binding was evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human C-X-C chemokine receptor type 2Compound binding was evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human C-X-C chemokine receptor type 2
ChEMBL 504 10 1 6 7.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1ccc(-c2cccs2)s1 10.1016/s0960-894x(01)00326-2
9849040 152031 2 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 504 10 1 6 7.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1ccc(-c2cccs2)s1 10.1016/s0960-894x(02)00188-9
CHEMBL39740 152031 2 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2
ChEMBL 504 10 1 6 7.9 CCN(CC)CCCCNc1nc2cc(Cl)c(Cl)cc2nc1-c1ccc(-c2cccs2)s1 10.1016/s0960-894x(02)00188-9
CHEMBL4776480 180804 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 408 3 2 5 4.7 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccc(F)cc2)sc2c1CCOC2 10.1016/j.ejmech.2020.112387
56839294 122231 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 379 6 3 5 1.8 CN(Cc1ccc(B(O)O)cc1)c1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL3609005 122231 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 379 6 3 5 1.8 CN(Cc1ccc(B(O)O)cc1)c1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
11222420 86064 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 368 2 3 7 2.5 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2 10.1016/j.bmcl.2007.05.011
CHEMBL231924 86064 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPRAntagonist activity at CXCR2 receptor expressed in CHOK1 cells assessed as human IL8-induced calcium mobilization by FLIPR
ChEMBL 368 2 3 7 2.5 O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2 10.1016/j.bmcl.2007.05.011
CHEMBL3104899 103916 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 305 4 2 5 2.0 OCc1cc2nc(CCc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
44447932 94980 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 456 10 3 4 3.9 CCCCNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL258038 94980 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 456 10 3 4 3.9 CCCCNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
44447931 154578 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 456 9 2 4 3.9 CCN(CC)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL403497 154578 0 CXCR2 CXCR2 Human 6.0 pIC50 = 6.0 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 456 9 2 4 3.9 CCN(CC)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL3104904 103919 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 431 6 1 8 4.8 Oc1cc(CSc2nc(-c3ccccc3)cs2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104906 103921 0 CXCR2 CXCR2 Human 5.0 pIC50 = 5.0 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 408 7 1 8 3.7 COc1ccc(SCc2cc(O)n3nc(Cc4ccccc4)nc3n2)c(OC)c1 10.1016/j.bmcl.2013.11.074
71550940 144850 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 469 7 3 8 3.6 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCSCC2)o1 nan
CHEMBL3915853 144850 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 469 7 3 8 3.6 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCSCC2)o1 nan
44419412 82521 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 435 5 3 5 3.8 CC(C)c1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL218334 82521 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 435 5 3 5 3.8 CC(C)c1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
46897355 126451 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 464 6 1 5 5.1 CC1(C)OB(c2ccc(CSc3ccc(C(=O)Nc4ccc(F)cc4)cn3)cc2)OC1(C)C nan
CHEMBL3658241 126451 0 CXCR2 CXCR2 Human 7.0 pIC50 = 7.0 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 464 6 1 5 5.1 CC1(C)OB(c2ccc(CSc3ccc(C(=O)Nc4ccc(F)cc4)cn3)cc2)OC1(C)C nan
44393543 12519 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 369 3 4 3 3.9 NCc1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL1188250 12519 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 369 3 4 3 3.9 NCc1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL535818 12519 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 369 3 4 3 3.9 NCc1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
134135498 143211 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3902863 143211 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
59446418 126462 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 434 7 2 7 3.6 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(-c2nn[nH]n2)cc1 nan
CHEMBL3658288 126462 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 434 7 2 7 3.6 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(-c2nn[nH]n2)cc1 nan
91937334 126478 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 384 6 3 7 1.2 O=C(Nc1ccc(F)cn1)c1cnc(SCc2ccccc2B(O)O)nc1 nan
CHEMBL3658340 126478 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 384 6 3 7 1.2 O=C(Nc1ccc(F)cn1)c1cnc(SCc2ccccc2B(O)O)nc1 nan
91937342 126485 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 471 6 2 7 3.4 O=C(Nc1ccc(F)cn1)c1ccc(S(=O)(=O)Cc2cc(OC(F)(F)F)ccc2O)nc1 nan
CHEMBL3658349 126485 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 471 6 2 7 3.4 O=C(Nc1ccc(F)cn1)c1ccc(S(=O)(=O)Cc2cc(OC(F)(F)F)ccc2O)nc1 nan
9868309 65030 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 447 4 3 4 3.7 CN(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
CHEMBL183222 65030 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Concentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cellsConcentration required to inhibit [125I]IL-8 binding towards C-X-C chemokine receptor type 2 of human expressed in CHO cells
ChEMBL 447 4 3 4 3.7 CN(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2ccccc2Br)c1O 10.1016/j.bmcl.2004.06.097
44419483 82605 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 564 8 4 7 3.6 CCC(CC)(NS(=O)(=O)c1cccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCOCC1 10.1016/j.bmcl.2006.08.042
CHEMBL218744 82605 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 564 8 4 7 3.6 CCC(CC)(NS(=O)(=O)c1cccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCOCC1 10.1016/j.bmcl.2006.08.042
44419546 83901 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 461 4 3 5 3.7 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2C(F)(F)F)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL222075 83901 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 461 4 3 5 3.7 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2C(F)(F)F)c1O 10.1016/j.bmcl.2006.08.042
44446645 94190 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2
ChEMBL 398 7 3 8 2.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)on1 10.1016/j.bmcl.2008.01.024
CHEMBL253927 94190 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2Inhibition of CXCR2-mediated chemotaxis in Ba/F3 cells expressing human CXCR2
ChEMBL 398 7 3 8 2.3 CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1cc(C)on1 10.1016/j.bmcl.2008.01.024
137637097 155270 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 4 3 4 3.8 CC1=CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4062881 155270 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 386 4 3 4 3.8 CC1=CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
58180198 140017 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 432 4 3 4 4.8 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
CHEMBL3818984 140017 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 432 4 3 4 4.8 O=C(Nc1ccc(Cl)c(S(=O)(=O)C2CCC2)c1O)Nc1cccc(F)c1Cl 10.1021/acsmedchemlett.5b00489
9910064 117277 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 420 8 3 7 2.7 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403835 117277 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 420 8 3 7 2.7 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
10345330 117288 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 486 9 3 9 2.9 C[C@H](CO)Nc1cc(NS(=O)(=O)c2cn(C)cn2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403847 117288 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 486 9 3 9 2.9 C[C@H](CO)Nc1cc(NS(=O)(=O)c2cn(C)cn2)nc(SCc2cccc(Cl)c2F)n1 10.1016/j.bmcl.2015.01.067
23519822 86557 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL232846 86557 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
23519825 148927 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 381 6 3 8 3.4 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL394799 148927 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 381 6 3 8 3.4 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
9969306 143097 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 368 6 3 10 2.5 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.11.039
CHEMBL390191 143097 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 368 6 3 10 2.5 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.11.039
9885291 97594 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 361 7 3 8 3.1 CC[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL274737 97594 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 361 7 3 8 3.1 CC[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
44447946 94312 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 515 6 3 3 5.0 O=C(NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12)NS(=O)(=O)c1ccccc1 10.1016/j.bmcl.2008.01.127
CHEMBL254773 94312 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 515 6 3 3 5.0 O=C(NCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12)NS(=O)(=O)c1ccccc1 10.1016/j.bmcl.2008.01.127
44447928 94929 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL257829 94929 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
44432392 87347 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2ccc(F)cc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL234396 87347 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2ccc(F)cc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
10018018 153137 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2 (CXCR2 filter mat binding assay)Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2 (CXCR2 filter mat binding assay)
ChEMBL 306 5 2 4 2.7 O=C(O)CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/s0960-894x(02)00188-9
CHEMBL39835 153137 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2 (CXCR2 filter mat binding assay)Displacement of [125I]IL-8 from CHO cell membranes expressing human CX3C chemokine receptor 2 (CXCR2 filter mat binding assay)
ChEMBL 306 5 2 4 2.7 O=C(O)CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/s0960-894x(02)00188-9
56839499 122236 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 380 6 3 6 1.2 CN(Cc1ccc(B(O)O)cc1)c1ncc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
CHEMBL3609011 122236 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysisAntagonist activity at CXCR2 (unknown origin) transfected in RBL cells assessed as inhibition of IL-8-mediated intracellular calcium release preincubated for 30 mins followed by IL-8 addition by FLUO-4AM-based fluorescent microplate reader analysis
ChEMBL 380 6 3 6 1.2 CN(Cc1ccc(B(O)O)cc1)c1ncc(C(=O)Nc2ccc(F)cc2)cn1 10.1016/j.bmcl.2015.07.090
46896583 114178 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 435 6 1 5 6.2 Cc1nc(-c2ccccc2)sc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
CHEMBL3342290 114178 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 435 6 1 5 6.2 Cc1nc(-c2ccccc2)sc1CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1 nan
46897354 126038 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 482 6 1 5 5.2 CC1(C)OB(c2ccc(F)cc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
CHEMBL3654445 126038 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 482 6 1 5 5.2 CC1(C)OB(c2ccc(F)cc2CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)OC1(C)C nan
91937329 126476 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 456 8 1 4 6.0 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)C(c2ccccc2)c2ccccc2)nc1 nan
CHEMBL3658336 126476 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 456 8 1 4 6.0 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)C(c2ccccc2)c2ccccc2)nc1 nan
91937341 126484 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 455 6 2 6 3.8 O=C(Nc1ccc(F)cn1)c1ccc([S+]([O-])Cc2cc(OC(F)(F)F)ccc2O)nc1 nan
CHEMBL3658348 126484 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 455 6 2 6 3.8 O=C(Nc1ccc(F)cn1)c1ccc([S+]([O-])Cc2cc(OC(F)(F)F)ccc2O)nc1 nan
136087080 115237 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 399 6 3 6 3.3 CC(C)Cc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
CHEMBL3355234 115237 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 399 6 3 6 3.3 CC(C)Cc1cc(=O)nc(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)[nH]1 10.1016/j.bmcl.2014.10.003
136087087 115244 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 417 6 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)CF)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355241 115244 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 417 6 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)CF)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087089 115246 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 403 5 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)F)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355243 115246 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 403 5 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C(C)(C)F)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
118540528 155242 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4062546 155242 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4097602 158286 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 427 5 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2C[C@H](N(C)C)C2)c1O 10.1021/acs.jmedchem.7b01854
129316051 155504 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 429 6 3 5 3.4 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4065522 155504 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 429 6 3 5 3.4 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)(C)CN(C)C)c1O 10.1021/acs.jmedchem.7b01854
9969306 143097 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 368 6 3 10 2.5 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.02.080
CHEMBL390191 143097 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 368 6 3 10 2.5 Cc1nc(CSc2nc(N[C@H](C)CO)c3sc(N)nc3n2)cs1 10.1016/j.bmcl.2007.02.080
45485756 191991 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 360 6 3 7 0.6 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)=O 10.1016/j.bmcl.2009.08.014
CHEMBL576886 191991 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxisAntagonist activity at CXCR2 expressed in CHO cells assessed as inhibition of IL-8-induced chemotaxis
ChEMBL 360 6 3 7 0.6 CCN(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)C(C)=O 10.1016/j.bmcl.2009.08.014
24769501 124394 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 445 8 2 4 4.7 CC(C)(NC(=O)c1ccc2ccccc2c1OCCOc1ccc(F)c(Cl)c1)C(=O)O nan
CHEMBL3645133 124394 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 445 8 2 4 4.7 CC(C)(NC(=O)c1ccc2ccccc2c1OCCOc1ccc(F)c(Cl)c1)C(=O)O nan
91937303 126467 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 500 6 1 5 6.4 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2csc3ccc(Br)cc23)nc1 nan
CHEMBL3658311 126467 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 500 6 1 5 6.4 O=C(Nc1ccc(F)cc1)c1ccc(SCC(=O)c2csc3ccc(Br)cc23)nc1 nan
71526251 149983 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 469 7 3 9 2.6 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@@H]2COC(C)(C)O2)o1 nan
CHEMBL3956663 149983 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 469 7 3 9 2.6 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)[C@@H]2COC(C)(C)O2)o1 nan
137644193 157469 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 5 2.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4088965 157469 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 376 4 3 5 2.5 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCOCC2)c1O 10.1021/acs.jmedchem.7b01854
11857680 96941 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
CHEMBL271013 96941 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysisDisplacement of [125I]-IL8 from human CXCR2 transfected in HEK293 cells after 4 hrs by microbeta counting analysis
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1021/jm3012273
44419449 165280 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 469 5 3 5 4.3 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2-c2ccccc2)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL425985 165280 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 469 5 3 5 4.3 CN(C)S(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2-c2ccccc2)c1O 10.1016/j.bmcl.2006.08.042
44439704 11610 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 538 6 3 8 2.3 CN1CCN(S(=O)(=O)c2c(F)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL1182475 11610 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 538 6 3 8 2.3 CN1CCN(S(=O)(=O)c2c(F)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
CHEMBL239982 11610 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 538 6 3 8 2.3 CN1CCN(S(=O)(=O)c2c(F)ccc(Nc3c(Nc4ccccc4Br)c(=O)c3=O)c2O)CC1 10.1016/j.bmcl.2006.12.067
23519822 86557 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL232846 86557 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2ccccc2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
44455234 94737 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 366 6 4 7 2.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(N)nc12 10.1016/j.bmcl.2007.11.039
CHEMBL257006 94737 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 366 6 4 7 2.3 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(N)nc12 10.1016/j.bmcl.2007.11.039
11857680 96941 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
CHEMBL271013 96941 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 347 6 3 8 2.8 C[C@H](CO)Nc1nc(SCc2ccccc2)nc2nc(N)sc12 10.1016/j.bmcl.2007.11.039
9967031 100241 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 324 4 1 4 1.5 CCS(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
CHEMBL294095 100241 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 324 4 1 4 1.5 CCS(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
9883149 196312 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 310 3 1 4 1.1 CS(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
CHEMBL61835 196312 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2Evaluated using an SPA assay with recombinant human [125I]IL-8 and membranes prepared from Sf9 cells expressing human CXCR2
ChEMBL 310 3 1 4 1.1 CS(=O)(=O)c1ccc(C(=O)Nc2ccc(F)cc2)c[n+]1[O-] 10.1016/s0960-894x(01)00326-2
46897163 118333 2 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Inhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assayInhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assay
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.bmcl.2015.04.041
CHEMBL3426944 118333 2 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Inhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assayInhibition of CXCR2 (unknown origin) expressed in PathHunter celline by beta-arrestin assay
ChEMBL 466 7 3 6 3.3 O=C(Nc1ccc(F)cc1)c1ccc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1 10.1016/j.bmcl.2015.04.041
136074340 112220 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
CHEMBL3310785 112220 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
44447928 94929 0 CXCR2 CXCR2 Rabbit 5.9 pIC50 = 5.9 Functional
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL257829 94929 0 CXCR2 CXCR2 Rabbit 5.9 pIC50 = 5.9 Functional
Antagonist activity at rabbit CXCR2 by neutrophil chemotaxis assayAntagonist activity at rabbit CXCR2 by neutrophil chemotaxis assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
135555955 135048 5 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 290 3 2 7 2.7 Nc1nc2nc(SCc3ccccc3)nc(O)c2s1 10.1016/j.bmcl.2005.10.091
CHEMBL373067 135048 5 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 290 3 2 7 2.7 Nc1nc2nc(SCc3ccccc3)nc(O)c2s1 10.1016/j.bmcl.2005.10.091
44447919 95067 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 427 8 2 4 4.0 CCCS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL258438 95067 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 427 8 2 4 4.0 CCCS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL3104905 103920 0 CXCR2 CXCR2 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 374 5 1 8 3.0 N#Cc1cccnc1SCc1cc(O)n2nc(Cc3ccccc3)nc2n1 10.1016/j.bmcl.2013.11.074
71525977 149402 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3951994 149402 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
71525977 149402 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3951994 149402 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL11359 76177 0 CXCR2 CXCR2 Human 4.9 pIC50 = 4.9 Binding
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
ChEMBL None None None None nan
CHEMBL2068237 76177 0 CXCR2 CXCR2 Human 4.9 pIC50 = 4.9 Binding
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)
ChEMBL None None None None nan
CHEMBL436940 167883 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 413 6 4 6 3.2 O=C(NCc1ccccc1)c1cccc(Nc2c(O)c(=O)/c2=N\c2ccccc2)c1O 10.1016/j.bmcl.2006.04.082
72948073 103914 0 CXCR2 CXCR2 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 461 7 1 7 3.7 CS(=O)(=O)Nc1cc(CSc2cccc(F)c2F)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104897 103914 0 CXCR2 CXCR2 Human 4.9 pIC50 = 4.9 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 461 7 1 7 3.7 CS(=O)(=O)Nc1cc(CSc2cccc(F)c2F)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
44447928 94929 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Functional
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL257829 94929 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Functional
Antagonist activity at human cloned CXCR2 by calcium flux FLIPR assayAntagonist activity at human cloned CXCR2 by calcium flux FLIPR assay
ChEMBL 414 7 3 4 2.7 CNS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL211247 78040 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human CXCR2 expressed in CHO cells
ChEMBL 331 2 3 6 1.3 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C(C)(C)C)c1O 10.1016/j.bmcl.2006.04.082
9841701 89894 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 357 5 4 6 2.2 NC(=O)c1c(Cl)ccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1016/j.bmcl.2006.12.067
CHEMBL238743 89894 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 357 5 4 6 2.2 NC(=O)c1c(Cl)ccc(Nc2c(Nc3ccccc3)c(=O)c2=O)c1O 10.1016/j.bmcl.2006.12.067
11625425 139667 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL380947 139667 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
91937313 126470 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 415 7 1 8 3.2 COC(=O)c1cc(C(=O)CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)on1 nan
CHEMBL3658321 126470 0 CXCR2 CXCR2 Human 7.9 pIC50 = 7.9 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 415 7 1 8 3.2 COC(=O)c1cc(C(=O)CSc2ccc(C(=O)Nc3ccc(F)cc3)cn2)on1 nan
135907764 112218 11 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
CHEMBL3310783 112218 11 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 319 4 1 5 3.5 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CC1 10.1016/j.bmcl.2014.06.011
CHEMBL4750465 179395 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Functional
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 359 4 3 6 1.9 CCC1NC(Nc2ccc(Cl)c(S(=O)(=O)C(C)C)c2O)=NC1=O 10.1021/acsmedchemlett.1c00113
44455117 154614 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 377 6 2 7 3.1 Cc1cnc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2n1 10.1016/j.bmcl.2007.11.039
CHEMBL403702 154614 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 377 6 2 7 3.1 Cc1cnc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2n1 10.1016/j.bmcl.2007.11.039
44447949 94338 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 462 6 3 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCNC(=O)NS(=O)(=O)c3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL254978 94338 0 CXCR2 CXCR2 Human 6.9 pIC50 = 6.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 462 6 3 4 4.1 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCNC(=O)NS(=O)(=O)c3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
135907767 112207 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 369 4 1 5 4.6 Cc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310773 112207 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 369 4 1 5 4.6 Cc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
136986993 112315 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 372 4 1 4 4.4 Oc1nc(SCc2cccc(F)c2F)nc(C2CC2)c1Br 10.1016/j.bmcl.2014.06.011
CHEMBL3311396 112315 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 372 4 1 4 4.4 Oc1nc(SCc2cccc(F)c2F)nc(C2CC2)c1Br 10.1016/j.bmcl.2014.06.011
24970093 126027 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 387 7 2 3 4.5 CC(C)(NC(=O)c1ccc2c(c1OCCC1CCCCC1)CCCC2)C(=O)O nan
CHEMBL3654433 126027 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Functional
Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.Calcium Fluorescence Assay: The assay is based on the detection of intracellular calcium changes detected by the selective, calcium-chelating dye, Fluo-4 (Molecular Probes). A large fluorescence intensity increase is observed upon calcium association with Fluo-4. The dye is delivered to the cell interior using an acetoxymethylester form of Fluo-4, where the intracellular esterase activity results in the charged species being released and trapped within the cytoplasm of the cell. hence, influx of calcium to this cytoplasmic pocket, via release from intracellular pools and the phospholipase C cascade can be detected. By co-expressing the CXCR2 receptor and the promiscuous Galpha 16 protein, activation of this chemokine receptor is directed into this phospholipase C cascade resulting in intracellular calcium mobilization.The CHOK1 cells stably transfected with human CXCR2 and the promiscuous Galpha 16 protein were maintained in a log phase of growth at 37 C. and 5% CO2 in the following media: Iscove's.
ChEMBL 387 7 2 3 4.5 CC(C)(NC(=O)c1ccc2c(c1OCCC1CCCCC1)CCCC2)C(=O)O nan
44407698 72649 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 453 9 3 9 4.9 CC[C@@H](CO)Nc1nc(SCc2cccc(Oc3ccccc3)c2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
CHEMBL201204 72649 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPADisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 membranes by SPA
ChEMBL 453 9 3 9 4.9 CC[C@@H](CO)Nc1nc(SCc2cccc(Oc3ccccc3)c2)nc2nc(N)sc12 10.1016/j.bmcl.2005.10.091
44447920 154680 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 475 8 2 4 4.8 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)Cc3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL404062 154680 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 475 8 2 4 4.8 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)Cc3ccccc3)c2c1 10.1016/j.bmcl.2008.01.127
9904302 199565 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 297 4 1 5 3.3 COc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
CHEMBL84957 199565 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 297 4 1 5 3.3 COc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
9903859 199878 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 281 3 1 4 3.6 Cc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
CHEMBL87282 199878 0 CXCR2 CXCR2 Human 5.9 pIC50 = 5.9 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 281 3 1 4 3.6 Cc1ccccc1-c1nc(S)n(Cc2ccccc2)n1 10.1016/s0960-894x(03)00561-4
CHEMBL214162 79668 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Functional
Inhibition of chemotaxis of CHO cells expressing human CXCR2Inhibition of chemotaxis of CHO cells expressing human CXCR2
ChEMBL 343 3 3 6 1.5 CN(C)C(=O)c1cccc(/N=c2\c(O)c(O)\c2=N/C2CCCC2)c1O 10.1016/j.bmcl.2006.04.082
71525696 132528 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 455 7 3 8 3.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)s1 nan
CHEMBL3704562 132528 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the .beta.-arrestin recruitment type after receptor activation.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 .beta.-arrestin line results in the recruitment of .beta.-arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170: 2904-2911.)In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with .beta.-arrestin 2, a .beta.-arrestin 2 recruitment test for CXCR2 or CXCR1 based on of .beta.-galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 455 7 3 8 3.0 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)COC2)s1 nan
46897449 114184 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2C(=O)O)nc1 10.1021/jm500827t
CHEMBL3342311 114184 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 382 6 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2C(=O)O)nc1 10.1021/jm500827t
46897449 114184 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2C(=O)O)nc1 nan
CHEMBL3342311 114184 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 382 6 2 4 4.5 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2C(=O)O)nc1 nan
151755055 172893 0 CXCR2 CXCR2 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 392 5 3 6 3.8 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nnc(-c3ccccc3)[nH]2)c1O 10.1016/j.ejmech.2019.111853
CHEMBL4536494 172893 0 CXCR2 CXCR2 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity at CXCR2 (unknown origin) stably expressed in HEK293 cells co-expressing Galpha16 assessed as reduction in IL-8-induced intracellular calcium change incubated for 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 392 5 3 6 3.8 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nnc(-c3ccccc3)[nH]2)c1O 10.1016/j.ejmech.2019.111853
CHEMBL4757674 180030 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Functional
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 522 7 4 8 3.4 CC(C)(C)OC(=O)NCCCS(=O)(=O)c1c(Cl)ccc(NC2=NC(=O)C(c3ccccc3)N2)c1O 10.1021/acsmedchemlett.1c00113
44419411 141048 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 421 5 3 5 3.2 CCc1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL386505 141048 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 421 5 3 5 3.2 CCc1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL209859 77437 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 305 3 3 6 2.2 N#Cc1ccc(Nc2c(O)c(=O)/c2=N\c2ccccc2)c(O)c1 10.1016/j.bmcl.2006.12.067
9821417 90013 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 383 4 3 6 3.1 N#Cc1ccc(Nc2c(Nc3ccccc3Br)c(=O)c2=O)c(O)c1 10.1016/j.bmcl.2006.12.067
CHEMBL239136 90013 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 383 4 3 6 3.1 N#Cc1ccc(Nc2c(Nc3ccccc3Br)c(=O)c2=O)c(O)c1 10.1016/j.bmcl.2006.12.067
44439701 90403 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 415 6 3 7 2.3 Cc1ccccc1Nc1c(Nc2ccc(C)c(S(=O)(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2006.12.067
CHEMBL239768 90403 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in CHO cells
ChEMBL 415 6 3 7 2.3 Cc1ccccc1Nc1c(Nc2ccc(C)c(S(=O)(=O)N(C)C)c2O)c(=O)c1=O 10.1016/j.bmcl.2006.12.067
9968028 82643 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 345 7 3 6 2.0 CCC(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1021/jm0609622
CHEMBL218964 82643 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 345 7 3 6 2.0 CCC(CC)Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O 10.1021/jm0609622
71526254 144014 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3909470 144014 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 523 8 3 8 4.3 Cc1ccc([C@H](Nc2c(Nc3cccc(C(=O)N(C)CC(F)(F)F)c3O)c(=O)c2=O)C2CCCS2)o1 nan
71525977 149402 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3951994 149402 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 455 7 3 8 3.4 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
136087083 115240 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 397 5 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355237 115240 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 397 5 3 6 3.3 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
136087086 115243 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 411 5 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3(C)CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
CHEMBL3355240 115243 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Antagonist activity at CXCR2 (unknown origin) by beta-arrestin assayAntagonist activity at CXCR2 (unknown origin) by beta-arrestin assay
ChEMBL 411 5 3 6 3.5 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nc(=O)cc(C3(C)CCC3)[nH]2)c1O 10.1016/j.bmcl.2014.10.003
11625425 139667 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Functional
Antagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPRAntagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPR
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL380947 139667 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Functional
Antagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPRAntagonistic activity against human CXCR2 in neutrophils assessed as blockade of GROalpha stimulated calcium mobilisation by FLIPR
ChEMBL 397 6 3 8 3.4 CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44431207 86595 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2cccc(F)c2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL233059 86595 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 365 6 3 8 2.9 C[C@H](CO)Nc1nc(SCc2cccc(F)c2)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44431210 86673 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 415 6 3 8 4.1 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2Cl)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL233260 86673 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 415 6 3 8 4.1 C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2Cl)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
44431171 142592 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 413 7 4 9 2.4 C[C@@H](O)[C@@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
CHEMBL389791 142592 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 413 7 4 9 2.4 C[C@@H](O)[C@@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2nc(N)sc12 10.1016/j.bmcl.2007.02.080
9841667 139950 39 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/j.ejmech.2020.112387
CHEMBL38182 139950 39 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 356 2 3 4 3.2 N#Cc1ccc(NC(=O)Nc2ccccc2Br)c2nn[nH]c12 10.1016/j.ejmech.2020.112387
CHEMBL3105080 103936 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 359 4 1 6 4.3 Oc1cc(CSc2cccc(F)c2F)nc2cc(-c3ccco3)nn12 10.1016/j.bmcl.2013.11.074
44447939 94255 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 470 7 2 5 2.9 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)N3CCOCC3)c2c1 10.1016/j.bmcl.2008.01.127
CHEMBL254366 94255 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 470 7 2 5 2.9 N#Cc1ccc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(=O)(=O)N3CCOCC3)c2c1 10.1016/j.bmcl.2008.01.127
44446578 94243 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 527 8 3 7 5.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2ccccc2C(F)(F)F)o1 10.1016/j.bmcl.2008.01.024
CHEMBL254308 94243 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 527 8 3 7 5.3 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(-c2ccccc2C(F)(F)F)o1 10.1016/j.bmcl.2008.01.024
136074340 112220 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
CHEMBL3310785 112220 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 391 6 1 7 3.3 CCOC(=O)[C@H]1C[C@@H]1c1nc(SCc2cccc(F)c2F)nc(O)c1C#N 10.1016/j.bmcl.2014.06.011
CHEMBL3102879 103671 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 308 3 1 6 2.7 Cc1nc2nc(CSc3cccc(F)c3F)cc(O)n2n1 10.1016/j.bmcl.2013.11.074
151755055 172893 0 CXCR2 CXCR2 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 392 5 3 6 3.8 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nnc(-c3ccccc3)[nH]2)c1O 10.1021/acsmedchemlett.1c00113
CHEMBL4536494 172893 0 CXCR2 CXCR2 Human 4.8 pIC50 = 4.8 Functional
Antagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assayAntagonist activity in CXCR2 (unknown origin) expressed in human HEK293 cells co-expressing Galpha16 assessed as reduction in calcium immobilization pretreated with Fluo-4AM for 45 mins followed by compound addition and measured after 10 mins by Fluo-4AM dye based fluorescence assay
ChEMBL 392 5 3 6 3.8 CC(C)S(=O)(=O)c1c(Cl)ccc(Nc2nnc(-c3ccccc3)[nH]2)c1O 10.1021/acsmedchemlett.1c00113
136060643 86893 0 CXCR2 CXCR2 Human 4.8 pIC50 = 4.8 Binding
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 303 2 3 5 1.9 CC[C@@H](C)NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
CHEMBL233551 86893 0 CXCR2 CXCR2 Human 4.8 pIC50 = 4.8 Binding
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 303 2 3 5 1.9 CC[C@@H](C)NC1=NS(=O)(=O)c2cc(Cl)cc(O)c2N1 10.1016/j.bmcl.2007.05.011
134149652 147401 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 513 11 4 11 2.6 COC(=O)CNCC(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
CHEMBL3935902 147401 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 513 11 4 11 2.6 COC(=O)CNCC(=O)c1cccc(Nc2c(NC(c3ccc(C)o3)C3CCCS3)c(=O)c2=O)c1O nan
71555288 147714 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 467 7 3 8 3.3 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCOCC2)o1 nan
CHEMBL3938406 147714 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).In Vitro Assay: The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the beta -arrestin recruitment after receptor activation type.It was demonstrated that the activation by CXCL8 of the CXCR2 receptor in cells of the PathHunter HEK293-CXCR2 line or of the CXCR1 receptor in cells of the U2OS h CXCR1 beta -arrestin line results in the recruitment of beta -arrestin (Richardson et al. 2003 Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation.>>J. Immunol. 170: 2904-2911).In order to evaluate the direct interaction of the CXCR2 or CXCR1 receptor with beta -arrestin 2, a beta -arrestin 2 recruitment test for CXCR2 or CXCR1 based on beta -galactosidase enzyme complementation (Olson K R, Eglen R M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol. 2007 February; 5(1); 137-44).
ChEMBL 467 7 3 8 3.3 Cc1ccc(C(Nc2c(Nc3cccc(C(=O)N(C)C)c3O)c(=O)c2=O)C2(C)CCOCC2)o1 nan
118540892 156910 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 377 3 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4082136 156910 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 377 3 3 5 3.1 CC1=CCC[C@H]1NC(=O)Nc1ccc(C#N)c(S(=O)(=O)C(C)(C)C)c1O 10.1021/acs.jmedchem.7b01854
118540525 158565 2 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4100674 158565 2 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysisAntagonist activity at CXCR2 in human whole blood assessed as inhibition of GROalpha-stimulated CD11b upregulation preincubated for 15 mins followed by GROalpha stimulation measured after 15 mins by FITC-staining based FACS analysis
ChEMBL 414 4 3 5 3.2 CC1=CCC[C@H]1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@]2(C)CCOC2)c1O 10.1021/acs.jmedchem.7b01854
137639152 156132 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 388 4 3 4 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC2(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4072677 156132 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 388 4 3 4 3.9 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)NC2CCCC2(C)C)c1O 10.1021/acs.jmedchem.7b01854
127049432 139954 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 436 4 3 4 5.2 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
CHEMBL3818216 139954 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 436 4 3 4 5.2 CC(C)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O 10.1021/acsmedchemlett.5b00489
127049048 139965 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 489 5 3 5 4.7 CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3818331 139965 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 489 5 3 5 4.7 CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
127049047 140055 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 491 4 3 5 4.9 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
CHEMBL3819521 140055 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 491 4 3 5 4.9 CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1 10.1021/acsmedchemlett.5b00489
57833203 117278 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 436 8 3 7 3.2 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(Cl)c2Cl)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403836 117278 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 436 8 3 7 3.2 C[C@H](CO)Nc1cc(NS(C)(=O)=O)nc(SCc2cccc(Cl)c2Cl)n1 10.1016/j.bmcl.2015.01.067
57833215 117280 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 396 10 3 7 2.7 CCCS(=O)(=O)Nc1cc(N[C@H](C)CO)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
CHEMBL3403838 117280 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysisDisplacement of [125I]IL-8 from human recombinant CXCR2 receptor expressed in HEK293 cells by scintillation counting analysis
ChEMBL 396 10 3 7 2.7 CCCS(=O)(=O)Nc1cc(N[C@H](C)CO)nc(SCc2ccccc2)n1 10.1016/j.bmcl.2015.01.067
137645186 157119 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 404 5 3 5 3.3 COC1CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
CHEMBL4084545 157119 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
Antagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assayAntagonist activity at TEV protease cleavage site linked GAL4-VP16-fused recombinant human CXCR2 expressed in cells assessed as inhibition of TEV protease tagged human CXCL1-stimulated beta-arrestin recruitment by CCF4-AM-fluorescence based FRET assay
ChEMBL 404 5 3 5 3.3 COC1CCCCC1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)C(C)C)c1O 10.1021/acs.jmedchem.7b01854
44431198 92635 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 455 10 3 9 3.3 CCN(CC)c1nc2nc(SCc3cccc(F)c3F)nc(NC(CO)CO)c2s1 10.1016/j.bmcl.2007.02.080
CHEMBL245182 92635 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
Displacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPADisplacement of [125I]IL8 from human CXCR2 expressed in HEK 293 by SPA
ChEMBL 455 10 3 9 3.3 CCN(CC)c1nc2nc(SCc3cccc(F)c3F)nc(NC(CO)CO)c2s1 10.1016/j.bmcl.2007.02.080
127049429 139927 0 CXCR2 CXCR2 Human 4.8 pIC50 = 4.8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 507 4 3 5 4.8 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
CHEMBL3817880 139927 0 CXCR2 CXCR2 Human 4.8 pIC50 = 4.8 Binding
Antagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader methodAntagonist activity at human recombinant CXCR2 assessed as inhibition of CXCL1-induced neutrophil chemotaxis after 45 mins by calcein-AM dye based plate reader method
ChEMBL 507 4 3 5 4.8 C[C@H]1CN(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C[C@@H](C)O1 10.1021/acsmedchemlett.5b00489
46896265 126454 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 426 7 1 6 4.4 O=C(Nc1ccc(F)cc1)c1ccc(SCCOc2cccc3c2OCCO3)nc1 nan
CHEMBL3658247 126454 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 426 7 1 6 4.4 O=C(Nc1ccc(F)cc1)c1ccc(SCCOc2cccc3c2OCCO3)nc1 nan
44419555 141142 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 626 9 5 7 4.5 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCC[C@@H]1C(=O)O 10.1016/j.bmcl.2006.08.042
CHEMBL387136 141142 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 626 9 5 7 4.5 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2Br)c1O)N1CCC[C@@H]1C(=O)O 10.1016/j.bmcl.2006.08.042
44455010 154602 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 403 6 3 7 2.6 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)c(C#N)cc12 10.1016/j.bmcl.2007.11.039
CHEMBL403656 154602 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assayDisplacement of [125I]IL8 from human recombinant CXCR2 expressed in HEK293 cells by SPA assay
ChEMBL 403 6 3 7 2.6 C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc2[nH]c(=O)c(C#N)cc12 10.1016/j.bmcl.2007.11.039
71526159 144596 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 525 8 3 9 3.6 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3913959 144596 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 525 8 3 9 3.6 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N(C)C)c3O)c(=O)c2=O)C2CCCS2)o1 nan
91937271 126460 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 445 7 1 6 5.0 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(Cl)c([N+](=O)[O-])c1 nan
CHEMBL3658278 126460 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 445 7 1 6 5.0 O=C(CSc1ccc(C(=O)Nc2ccc(F)cc2)cn1)c1ccc(Cl)c([N+](=O)[O-])c1 nan
44446605 94158 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1occc1Br 10.1016/j.bmcl.2008.01.024
CHEMBL253707 94158 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 461 7 3 7 3.4 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1occc1Br 10.1016/j.bmcl.2008.01.024
44447924 154687 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 429 7 2 5 3.3 COc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(C)(=O)=O)c2cc1C#N 10.1016/j.bmcl.2008.01.127
CHEMBL404088 154687 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 429 7 2 5 3.3 COc1cc2[nH]c(-c3ccc(F)cc3)c(CCCC(=O)NS(C)(=O)=O)c2cc1C#N 10.1016/j.bmcl.2008.01.127
135907774 112209 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 413 6 1 6 5.1 CC(C)Oc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
CHEMBL3310775 112209 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 413 6 1 6 5.1 CC(C)Oc1ccc(-c2nc(SCc3cccc(F)c3F)nc(O)c2C#N)cc1 10.1016/j.bmcl.2014.06.011
CHEMBL4787874 181697 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 418 4 2 5 4.8 C[C@@H](NC(=S)Nc1sc2c(c1C(=O)OC(C)(C)C)CCOC2)c1ccccc1 10.1016/j.ejmech.2020.112387
CHEMBL4798569 182544 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 474 4 2 6 5.5 CC(C)(C)OC(=O)c1c(NC(=S)Nc2ccc(OC(F)(F)F)cc2)sc2c1CCOC2 10.1016/j.ejmech.2020.112387
44432394 152581 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2c(F)cccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
CHEMBL397869 152581 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
Displacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cellsDisplacement of human recombinant [125I]IL8 from CXCR2 receptor expressed in CHO cells
ChEMBL 419 1 3 5 3.5 O=S1(=O)N=C(Nc2c(F)cccc2Br)Nc2c(O)cc(Cl)cc21 10.1016/j.bmcl.2007.05.011
46897452 114180 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 406 5 1 3 6.1 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(Cl)c(Cl)c2)nc1 10.1021/jm500827t
CHEMBL3342303 114180 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 406 5 1 3 6.1 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(Cl)c(Cl)c2)nc1 10.1021/jm500827t
46897452 114180 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 406 5 1 3 6.1 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(Cl)c(Cl)c2)nc1 nan
CHEMBL3342303 114180 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 406 5 1 3 6.1 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccc(Cl)c(Cl)c2)nc1 nan
91937336 126481 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 417 6 3 6 2.5 O=C(Nc1ccc(F)cn1)c1cnc(SCc2ccccc2B(O)O)c(Cl)c1 nan
CHEMBL3658343 126481 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).In Vitro Inhibition Assay: An in vitro assay showed inhibition of CXCR2-mediated intracellular calcium release. Briefly, human neutrophils were suspended in HBSS- (without Ca2+ and Mg2+) containing 10 mM HEPES and FLIPR Calcium 3 dye (3.1x107 cells in total volume 1.7 mL). Cells were aliquoted (200 uL of the cell suspension per tube, 8 tubes total) and 2 uL of the designated compound (with appropriate dilutions) were added to each of 6 tubes. As controls, 2 uL of DMSO (1% final concentration) were added to 2 other tubes. Cells were incubated for 30 min at 37 C. After dye loading, tubes were centrifuged at 6,000 rpm for 1 min, supernatant was removed and the cell pellet was re-suspended in 200 uL of HBSS+ (with Ca2+ and Mg2+) containing 10 mM HEPES. The test compound or DMSO (control) was added again at the same concentrations that were used during cell loading. The cell suspension was aliquoted into a 96-well Reading Plate (Corning) in a volume of 90 uL (105 cells/well).
ChEMBL 417 6 3 6 2.5 O=C(Nc1ccc(F)cn1)c1cnc(SCc2ccccc2B(O)O)c(Cl)c1 nan
57864041 124396 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 399 6 2 2 4.8 CC(C)(NC(=O)c1ccc2ccccc2c1C#CCCCc1ccccc1)C(=O)O nan
CHEMBL3645135 124396 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).Calcium Fluorescence Assay (FLIPR) : CXCR2 inhibition using calcium fluorescence assay (FLIPR).
ChEMBL 399 6 2 2 4.8 CC(C)(NC(=O)c1ccc2ccccc2c1C#CCCCc1ccccc1)C(=O)O nan
135286501 171276 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 546 8 3 10 2.6 Cc1ccc([C@H](Nc2c(Nc3cccc(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)[C@H]2CCCS2)o1 10.1016/j.ejmech.2019.111853
CHEMBL4472754 171276 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Antagonist activity at CXCR2 (unknown origin)Antagonist activity at CXCR2 (unknown origin)
ChEMBL 546 8 3 10 2.6 Cc1ccc([C@H](Nc2c(Nc3cccc(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)[C@H]2CCCS2)o1 10.1016/j.ejmech.2019.111853
44419439 83571 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 407 4 3 5 3.0 Cc1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
CHEMBL220860 83571 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 407 4 3 5 3.0 Cc1ccccc1N/C(=N\C#N)Nc1ccc(Cl)c(S(=O)(=O)N(C)C)c1O 10.1016/j.bmcl.2006.08.042
44419476 135604 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 562 8 4 7 4.6 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2C)c1O)N1C[C@H](C)O[C@H](C)C1 10.1016/j.bmcl.2006.08.042
CHEMBL373522 135604 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]IL8 from CXCR2 expressed in CHO cellsDisplacement of [125I]IL8 from CXCR2 expressed in CHO cells
ChEMBL 562 8 4 7 4.6 CCC(CC)(NS(=O)(=O)c1c(Cl)ccc(N/C(=N/C#N)Nc2ccccc2C)c1O)N1C[C@H](C)O[C@H](C)C1 10.1016/j.bmcl.2006.08.042
16098485 10133 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 379 6 3 6 2.6 C[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
CHEMBL1162935 10133 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Displacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cellsDisplacement of [125I]hCXCL8 from human CXCR2 receptor expressed in BaF3 cells
ChEMBL 379 6 3 6 2.6 C[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccccc1 10.1021/jm0609622
71526345 149524 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 580 8 3 10 3.3 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)C2CCCS2)o1 nan
CHEMBL3952996 149524 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 580 8 3 10 3.3 Cc1ccc(C(Nc2c(Nc3ccc(Cl)c(S(=O)(=O)N4CCN(C)CC4)c3O)c(=O)c2=O)C2CCCS2)o1 nan
44446568 154728 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 451 7 3 7 3.6 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)(F)F)o1 10.1016/j.bmcl.2008.01.024
CHEMBL404250 154728 0 CXCR2 CXCR2 Human 7.8 pIC50 = 7.8 Binding
Inhibition of CXCR2Inhibition of CXCR2
ChEMBL 451 7 3 7 3.6 CCC(Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C(F)(F)F)o1 10.1016/j.bmcl.2008.01.024
46897451 114185 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 406 6 2 6 3.9 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2-c2nn[nH]n2)nc1 10.1021/jm500827t
CHEMBL3342312 114185 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Functional
Antagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assayAntagonist activity at CXCR2 in human PMNs assessed as inhibition of CXCL1-induced intracellular Ca2+ release by fluorescence based calcium flux assay
ChEMBL 406 6 2 6 3.9 O=C(Nc1ccc(F)cc1)c1ccc(SCc2ccccc2-c2nn[nH]n2)nc1 10.1021/jm500827t
44447917 94423 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 452 6 2 3 4.1 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
CHEMBL255481 94423 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Displacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assayDisplacement of europium labeled-human IL8 from human cloned CXCR2 expressed in Sf9 membrane with Galphai3-beta-1-gamma-2 by DELFIA binding assay
ChEMBL 452 6 2 3 4.1 CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(Br)cc12 10.1016/j.bmcl.2008.01.127
71526341 152765 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 435 7 3 7 2.8 CN(C)C(=O)c1cccc(Nc2c(NC(c3ccccc3)C3CCCO3)c(=O)c2=O)c1O nan
CHEMBL3980279 152765 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).In Vitro Affinity Assay: â¿¿PathHunter HEK293-CXCR2⿝ or â¿¿U2OS hCXCR1 β-arrestin⿝ cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in 20 μl of Opti MEM I medium. A preincubation with the antagonist or the vehicle for 30 min at 37° C. and 5% CO2 was followed by 60 minutes of stimulation with CXCL8 at 37° C. and 5% CO2. The cells were then placed at ambient temperature for 30 minutes. The PathHunter detection reagent (DiscoveRx Corporation) was added. After incubation for 60 min at ambient temperature, the β-galactosidase induced by the luminescence during the β-arrestin-CXCR2 interaction was measured for 0.3 s in an Envision 2102 Multilabel Reader (PerkinElmer Life and Analytical Sciences).
ChEMBL 435 7 3 7 2.8 CN(C)C(=O)c1cccc(Nc2c(NC(c3ccccc3)C3CCCO3)c(=O)c2=O)c1O nan
44318556 106329 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 427 5 1 5 6.4 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1cccc(Oc2ccccc2)c1 10.1016/s0960-894x(03)00561-4
CHEMBL315588 106329 0 CXCR2 CXCR2 Human 6.8 pIC50 = 6.8 Binding
Inhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranesInhibition of binding of [125I]IL8 to human recombinant CXC chemokine receptor 2 (CXCR2) expressed in HEK 293 membranes
ChEMBL 427 5 1 5 6.4 Sc1nc(-c2ccc(Cl)cc2Cl)nn1Cc1cccc(Oc2ccccc2)c1 10.1016/s0960-894x(03)00561-4
135907781 112217 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 333 4 1 5 3.9 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CCC1 10.1016/j.bmcl.2014.06.011
CHEMBL3310782 112217 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assayAntagonist activity against human recombinant CXCR2 receptor expressed in CHO cell membranes by SPA based [35S]GTPgammaS binding assay
ChEMBL 333 4 1 5 3.9 N#Cc1c(O)nc(SCc2cccc(F)c2F)nc1C1CCC1 10.1016/j.bmcl.2014.06.011
CHEMBL4795943 182334 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Binding
Antagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assayAntagonist activity at CXCR2 (unknown origin) expressed in U2OS cells cotransfected with beta-arrestin/TEV protease fusion protein and beta-lactamase assessed as inhibition of CXCL8-induced beta arrestin2 recruitment preincubated for 30 mins followed by CXCL8 stimulation and measured after 5 hrs by FRET based fluorescence/Tango assay
ChEMBL 404 3 2 5 5.1 CC1COCc2sc(NC(=S)Nc3ccccc3)c(C(=O)OC(C)(C)C)c21 10.1016/j.ejmech.2020.112387
CHEMBL3104911 103926 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 416 5 1 6 5.0 Oc1cc(CSc2cccc(Cl)c2Cl)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3104913 103928 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 384 5 1 6 4.0 Oc1cc(CSc2ccc(F)c(F)c2)nc2nc(Cc3ccccc3)nn12 10.1016/j.bmcl.2013.11.074
CHEMBL3105083 103939 0 CXCR2 CXCR2 Human 5.8 pIC50 = 5.8 Functional
Antagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA methodAntagonist activity at human recombinant CXCR2 receptor expressed in CHO cells assessed as inhibition of IL8-induced [35S]GTPgammaS binding by SPA method
ChEMBL 347 3 1 5 3.9 Oc1cc(CSc2cccc(F)c2F)nc2c3c(nn12)CCCC3 10.1016/j.bmcl.2013.11.074
44447946